Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026
Johnson & Johnson (NYSE:JNJ) is among the most profitable US stocks to buy.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 13,949 | $2,886,720 | -4% | 1.38% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 10,964 | $2,269,000 | +2% | 0.05% |
| 3. | Bourgeon Capital John Zaro | 10,134 | $2,097,232 | +98% | 0.34% |
| 4. | Hourglass Capital Kenneth A. Moffet | 8,860 | $1,833,577 | -1% | 0.4% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $192.71 | 21,721 | $4,185,793.09 | 10,658 | 2025-10-17 | Filing | |
| $177.81 | 56,471 | $10,040,882.63 | 178,013 | 2025-09-04 | Filing | |
| $179.21 | 125,824 | $22,548,654.81 | 275,967 | 2025-08-22 | Filing | |
| $176.91 | 16,820 | $2,975,570.69 | 14,000 | 2025-08-15 | Filing | |
| $163.55 | 19,137 | $3,129,829.56 | 10,658 | 2025-07-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,460,452 | $1,128,675,429 | 0.97% | |
| 2. | 2,067,667 | $427,903,686 | 2.66% | |
| 3. | 1,936,788 | $396,755,382 | 0.54% | |
| 4. | 1,500,217 | $310,469,914 | 1.65% | |
| 5. | 1,368,761 | $283,265,089 | 0.39% |
News See All
10 Most Profitable US Stocks to Buy
Investing in the stock market can be both exciting and challenging, particularly when the investor has to identify a stock that not only generates healthy margins and delivers strong returns but also ...
Jim Cramer Shared His Thoughts on These 16 Stocks
“You never want to see what's happening right now in the stock market. You see, the market's developing a thesis, and it's not the thesis you and I were hoping for.
Here’s What Lifted Johnson & Johnson (JNJ) in Q4
Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S.
Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs
On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares.
Jim Cramer Offered Insights on These 16 Stocks
“I need you to understand what makes my approach different from the conventional wisdom. It's all rooted in the sales and trading I did for 20 years before Mad Money started.
Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar
On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Here’s Why Johnson & Johnson (JNJ) Surged in Q3
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs
Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck.
Hedge Fund Resource Center Billionaire Hedge Funds
